These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 26135230)

  • 1. Formulation development and systematic optimization of stabilized ziprasidone hydrochloride capsules devoid of any food effect.
    Banerjee S; Shankar KR; Prasad Y R
    Pharm Dev Technol; 2016 Nov; 21(7):775-786. PubMed ID: 26135230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Combined Utilization of Plasdone-S630 and HPMCAS-HF in Ziprasidone Hydrochloride Solid Dispersion by Hot-Melt Extrusion to Enhance the Oral Bioavailability and No Food Effect.
    Xue X; Chen G; Xu X; Wang J; Wang J; Ren L
    AAPS PharmSciTech; 2019 Jan; 20(1):37. PubMed ID: 30604142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and evaluation of self-nanoemulsifying sustained-release pellet formulation of ziprasidone with enhanced bioavailability and no food effect.
    Miao Y; Chen G; Ren L; Pingkai O
    Drug Deliv; 2016 Sep; 23(7):2163-2172. PubMed ID: 25148542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and evaluation of ziprasidone-phospholipid complex from sustained-release pellet formulation with enhanced bioavailability and no food effect.
    Miao Y; Chen G; Ren L; Ouyang P
    J Pharm Pharmacol; 2016 Feb; 68(2):185-94. PubMed ID: 26748446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solid nanocrystalline dispersions of ziprasidone with enhanced bioavailability in the fasted state.
    Thombre AG; Caldwell WB; Friesen DT; McCray SB; Sutton SC
    Mol Pharm; 2012 Dec; 9(12):3526-34. PubMed ID: 23075293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro.
    Dening TJ; Rao S; Thomas N; Prestidge CA
    Eur J Pharm Biopharm; 2016 Apr; 101():33-42. PubMed ID: 26812284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The improvement of the dissolution rate of ziprasidone free base from solid oral formulations.
    Zakowiecki D; Cal K; Kaminski K; Adrjanowicz K; Swinder L; Kaminska E; Garbacz G
    AAPS PharmSciTech; 2015 Aug; 16(4):922-33. PubMed ID: 25588366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled release of ziprasidone solid dispersion systems from osmotic pump tablets with enhanced bioavailability in the fasted state.
    Yanfei M; Guoguang C; Lili R; Pingkai O
    Drug Dev Ind Pharm; 2015; 41(8):1353-62. PubMed ID: 25138348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of food on the absorption of oral ziprasidone.
    Miceli JJ; Glue P; Alderman J; Wilner K
    Psychopharmacol Bull; 2007; 40(3):58-68. PubMed ID: 18007569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
    Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanocrystal-silica-lipid hybrid particles for the improved oral delivery of ziprasidone in vitro.
    Meola TR; Dening TJ; Prestidge CA
    Eur J Pharm Biopharm; 2018 Aug; 129():145-153. PubMed ID: 29857135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect.
    Thombre AG; Herbig SM; Alderman JA
    Pharm Res; 2011 Dec; 28(12):3159-70. PubMed ID: 21674263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone.
    Lincoln J; Stewart ME; Preskorn SH
    J Psychiatr Pract; 2010 Mar; 16(2):103-14. PubMed ID: 20511734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations.
    Thombre AG; Shah JC; Sagawa K; Caldwell WB
    Int J Pharm; 2012 May; 428(1-2):8-17. PubMed ID: 22349051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.
    Guivarc'h PH; Vachon MG; Fordyce D
    Clin Ther; 2004 Sep; 26(9):1456-69. PubMed ID: 15531008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect.
    Solymosi T; Ötvös Z; Angi R; Ordasi B; Jordán T; Molnár L; McDermott J; Zann V; Church A; Mair S; Filipcsei G; Heltovics G; Glavinas H
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):723-728. PubMed ID: 28776077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using oral ziprasidone effectively: the food effect and dose-response.
    Citrome L
    Adv Ther; 2009 Aug; 26(8):739-48. PubMed ID: 19669631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.